TY - CHAP M1 - Book, Section TI - Small Cell Lung Cancer: Diagnosis, Treatment, and Natural History A1 - Dowell, Jonathan E. A1 - Gerber, David E. A1 - Johnson, David H. A2 - Grippi, Michael A. A2 - Elias, Jack A. A2 - Fishman, Jay A. A2 - Kotloff, Robert M. A2 - Pack, Allan I. A2 - Senior, Robert M. A2 - Siegel, Mark D. Y1 - 2015 N1 - T2 - Fishman's Pulmonary Diseases and Disorders, 5e AB - Small cell lung cancer (SCLC) is, in many ways, a unique tumor. Untreated, it is a highly virulent malignancy, with a life expectancy best measured in weeks. Conversely, it displays exquisite chemosensitivity, resulting in partial or complete responses in the majority of cases. Unfortunately, these responses are typically short-lived, and as a result, more than 95% of SCLC patients die from their disease. Over the past 25 years, little progress has been made in prolonging the survival of patients with SCLC, despite numerous attempts to refine and improve the present therapy. This chapter reviews the biology, epidemiology, diagnosis, clinical presentation, staging, and current management of this difficult disease. SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/03/28 UR - accessmedicine.mhmedical.com/content.aspx?aid=1122367749 ER -